ArticleOpen forum infectious diseases2024
Global Epidemiology and Seasonality of Human Seasonal Coronaviruses: A Systematic Review.
Article in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- A decade of endemic human coronaviruses: epidemiological patterns and clinical significance in an adult cohort at a tertiary care hospital in Germany.BMC infectious diseases · 2026Article
- Near-complete genomes from six human coronavirus HKU1-positive samples recovered by metagenomics in coastal Kenya, 2024-2025.Microbiology resource announcements · 2026Article
- A stable subgenomic reporter coronavirus enables transcriptional profiling of bystander cells.The Journal of general virology · 2026Article
- Molecular Surveillance of Coronaviruses in Riyadh (2025-2026): Persistent Genotype C and Conserved N-Glycosylation Motifs in Human Coronavirus OC43.International journal of molecular sciences · 2026Article
- Article
- Etiological landscape and co-infection dynamics in Acute Respiratory Infections (ARIs): insights from a multicenter outpatient study in Yunnan, China.BMC infectious diseases · 2026Article
- Declined Circulation and Seasonal Shifts of Human Coronavirus 229E in the Republic of Korea: Implications for Respiratory Virus Surveillance.Pathogens (Basel, Switzerland) · 2026Article
- Epidemiological characteristics of human coronaviruses among populations with acute respiratory infections: surveillance data from jing'an district, Shanghai, 2024-2025.Preventive medicine reports · 2026Article
- Shifting patterns of pediatric respiratory viruses during the SARS-CoV-2 pandemic: a retrospective observational study.BMC infectious diseases · 2026Observational
- Spatiotemporal dynamics and phylogeography of HCoV-NL63 and HCoV-OC43 in Thailand, 2024-2025.PloS one · 2026Article
- Respiratory infections and asthma exacerbations in children: Regional insights into the overlooked role of atypical pathogens in Mexico.The journal of allergy and clinical immunology. Global · 2026Article
- A longitudinal study of antibody responses to endemic HCoV and novel SARS-CoV-2 among mother-child pairs in Zambia.BMC infectious diseases · 2025Article
- Current Status and Challenges of Vaccine Development for Seasonal Human Coronaviruses.Vaccines · 2025Review
- Copper-Silver Nanoparticle/Lipase Nanobiohybrids for Enhanced Activity Against Viral Pathogens.ACS applied nano materials · 2025Article
- Comprehensive analysis of human coronavirus antibody responses in ICU and non-ICU COVID-19 patients reveals IgG3 against SARS-CoV-2 spike protein as a key biomarker of disease severity.Journal of medical microbiology · 2025Article
- Epidemiology, Clinical Significance, and Diagnosis of Respiratory Viruses and Their Co-Infections in the Post-COVID Era.Pathogens (Basel, Switzerland) · 2025Review
- Shifting respiratory pathogens: Post-COVID-19 trends in community-acquired infections in underserved communities.PloS one · 2025Article
- Characterization and immunogenicity of nanoparticle vaccines displaying embecovirus spike proteins.Biotechnology progressArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: We characterized the global epidemiology and seasonality of human coronaviruses (HCoVs) OC43, NL63, 229E, and HKU1. Methods: In this systematic review, we searched MEDLINE, EMBASE, Web of Science, SCOPUS, CINAHL, and backward citations for studies published until 1 September 2023. We included studies with ≥12 months of consecutive data and tested for ≥1 HCoV species. Case reports, review articles, animal studies, studies focusing on SARS-CoV-1, SARS-CoV-2, and/or Middle East respiratory syndrome, and those including <100 cases were excluded. Study quality and risk of bias were assessed using Joanna Briggs Institute Critical Appraisal Checklist tools. We reported the prevalence of all HCoVs and individual species. Seasonality was reported for studies that included ≥100 HCoVs annually. This study is registered with PROSPERO, CRD42022330902. Results: A total of 201 studies (1 819 320 samples) from 68 countries were included. A high proportion were from China (19.4%; n = 39), whereas the Southern Hemisphere was underrepresented. Most were case series (77.1%, n = 155) with samples from secondary care (74.1%, n = 149). Seventeen (8.5%) studies included asymptomatic controls, whereas 76 (37.8%) reported results for all 4 HCoV species. Overall, OC43 was the most prevalent HCoV. Median test positivity of OC43 and NL63 was higher in children, and 229E and HKU1 in adults. Among 18 studies that described seasonality (17 from the Northern Hemisphere), circulation of all HCoVs mostly peaked during cold months. Conclusions: In our comprehensive review, few studies reported the prevalence of individual HCoVs or seasonality. Further research on the burden and circulation of HCoVs is needed, particularly from Africa, South Asia, and Central/South America.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.